Vol. 5, Issue 8 (2019)
Voglibose and its significance in prediabetes: An observational study
Author(s): Dr. Md. Mansoor Ali Khan Lodhi, Dr. Anjum Sultana Khatoon
Abstract: Aim: to achieve glycemic control in prediabetic patient with Alpha glucosidase inhibitors who are risk of developing frank diabetes mellitus. Material and Methods: In the present study a total of 150 prediabetic patients were selected out of which only 100 participants were eligible for study. Inclusion Criteria: 1) Age: 20-60yrs, 2) FBS: 101-125mg/dl, PPBS: 141 -199mg/dl, 3) BMI: 24-29 4) HbA1c: 5.7-6.4%. Exclusion Criteria: 1) Known Diabetic 2) Any h/o of intake of oral Hypoglycemic Agents 3) Preexisting CAD, Renal Dysfunction, Hepatic Dysfunction, Gastro-intestinal Disorders. Results: 100 eligible patients were enrolled as per Inclusion criteria, they were divided into two groups, Group 1 (n=53) was placed on Diet, lifestyle modification and Voglibose 0.3mg twice a day, whereas the Group B (n=47) was placebo group. The mean duration of treatment was 24·6 weeks (SD 18.4)—i.e.23.6 weeks (17·5) for voglibose and 25·4 weeks (18.9) for placebo. In group A (n=53), there were 23 males (43.39%), and 30 female subjects (56.60%), whereas in the placebo arm (n=47), there were 20 males (42.55%), 27 Female (57.44%). In the analysis, we found that patients on voglibose was better and the glycemic control was within the standard recommended lines than placebo in individuals Conclusion:A systematic approach and close monitoring that increased the adherence to medication, diet, and counselling would help in better glycemic control and prevent long term complication. In patient with prediabetes, early intervention with medication can prevent long term complication and also prevents or delays the onset of frank diabetes mellitus.